Akynzeo IV (fosnetupitant/palonosetron)
Customize your policy alerts
Sign up for Geisinger Health Plan Policy MBP 192.0 alerts
Get alerted when Policy MBP 192.0 changes without checking for updates manually.
Monitor payer policy activity
Medical benefit pharmaceutical policy governing prior authorization and medical necessity criteria for Akynzeo IV for prevention of chemotherapy-induced nausea and vomiting across applicable Geisinger Health Plan lines of business.
No material clinical or coverage changes in this revision.
Coverage Criteria for Akynzeo IV
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.